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Purpose: The purpose of this study is to evaluate the effect of contrast agent charge on the contrast agent
uptake ratio (CUR) in cartilage and to image the naturally occurring variations in glycosaminoglycan
(GAG) content present in bovine articular cartilage.
Methods: In an ex vivo bovine osteochondral plug model, we utilized three charged contrast agents
(Gadopentetate/Magnevist [2], Ioxaglate/Hexabrix [1], and CA4þ [þ4]) and mCT to image cartilage.
The X-ray attenuation of the cartilage tissue after equilibration in each contrast agent was also related to
the initial X-ray attenuation of each contrast agent in solution to compute the uptake of the respective
contrast agent (i.e., the CUR).
Results: Use of the cationic contrast agent resulted in signiﬁcantly higher equilibrium X-ray attenuations
in cartilage ECM than either of the anionic contrast agents (Gadopentetate [2] and Ioxaglate [1]). The
CUR (Mean SD) as computed in this study was 2.38 (0.26) for the cationic contrast agent indicating
a 2.38 fold increase in computed tomography (CT) attenuation of the cartilage. For the anionic contrast
agents, the CUR was 0.62 (0.26) for Ioxaglate [1] and 0.52 (0.17) for Gadopentetate [2], indicating
exclusion of 38% Ioxaglate and 48% Gadopentetate from the cartilage extracellular matrix. The cationic
contrast agent exhibited signiﬁcant correlations between CT attenuation and GAG content whereas
Ioxaglate and Gadopentetate did not (R2¼ 0.83 for CA4þ, R2¼ 0.20 for Ioxaglate, and R2¼ 0.22 for
Gadopentetate).
Conclusion: Electrostatic attraction of CA4þ allowed effective imaging of the GAG components of articular
cartilage at 50% lower molar concentration than Ioxaglate and 20-fold lower molar concentration than
Gadopentetate. The CA4þ contrast agent exhibited a signiﬁcant correlation between CT attenuation and
GAG content in ex vivo bovine osteochondral plugs.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis is a non-inﬂammatory disease of the diarthrodial
joints arising from the breakdown of hyaline cartilage as a result of
trauma,excessive joint loading,mechanical instability, and/or life-long.W. Grinstaff, Department of
monwealth Ave, Boston, MA
to: B.D. Snyder, Center for
Medical Center, 1 Overland
B.D. Snyder), mgrin@bu.edu
s Research Society International. Puse1e4. Imaging techniques to quantify the glycosaminoglycan (GAG)
content of cartilage are of signiﬁcant interest as loss of GAGs is an early
marker of osteoarthritis5. Of the imaging techniques investigated
today6 including magnetic resonance imaging (MRI)7e21, ultra-
sound22e24, and optical coherence tomography25e27, our interest is in
computed tomography (CT). Speciﬁcally, contrast enhancedcomputed
tomography (CECT) imaging techniques can be used to quantify the
GAG content28e38 and biomechanical properties37,39 of articular
cartilage. Most of the above studies have utilized commercially avail-
able anionic iodinated (Iothalamate39 and Ioxaglate28e35) or gadoli-
nium36,40 based contrast agents. These agents diffuse into cartilage
which is primarily composed of proteoglycans (5e10% wet weight.),
type II collagen (10e20% wet weight.) and water (68e85%)41,42. Their
presence in the tissue affords a higher CTattenuation and this signal isublished by Elsevier Ltd. All rights reserved.
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of cartilage are anionic polysaccharides that confer articular cartilage
with a negative ﬁxed charge density, these anionic contrast agents
partition in the cartilage in inverse proportion to the cartilage GAG
content. For these anionic contrast agents, high concentrations of the
agent (80e300mg of iodine per mL of solution) give the best results
with strong linear correlations between CECT attenuation and GAG
content28,29,32e35. However, lowering the contrast agent concentra-
tion results in a decrease in the sensitivity of the contrast agent to
changes in GAG content29,33. Ideally, the contrast agent should
increase the attenuation in the cartilage to higher levels than its own
starting attenuation, quantitatively monitor changes in GAG content,
afford images which represent the structure of the tissue, and require
a minimal concentration of contrast agent to fulﬁll all the above
requirements.
In this study, a recently reported cationic contrast agent bearing
four formal positive charges (CA4þ)33 was compared to two
frequently used anionic contrast agents, Ioxaglate (Hexabrix,
Mallinckrodt, St. Louis, MO, USA) and Gadopentetate (Magnevist,
Bayer Pharmaceuticals, Pittsburgh, PA, USA) as shown in Fig. 1. The
CA4þ and Ioxaglate have the same number of iodine atoms per
molecule and similar molecular weights and sizes. Ioxaglate in
conjunction with CT has been used by many investigators29,32,34,35
to quantitatively monitor GAGs in articular cartilage. Gadopente-
tate is the contrast agent used in delayed Gadolinium Enhanced
MRI of Cartilage (dGEMRIC)14,15,43,44 and has also been used to
image GAGs in bovine nasal cartilage using mCT36. The concentra-
tions of contrast agent solutions used in this study were chosen in
order to: (1) replicate previously published results, (2) characterize
the uptake or partitioning of the contrast agent into the cartilage
extracellular matrix, and (3) determine if a reduced concentration
of CA4þ, compared to Ioxaglate and Gadopentetate, could be used
for adequate CECT imaging of cartilage. After establishing the
imaging conditions with several test runs, the CA4þ CT agent was
used at 50% lesser molar concentration than Ioxaglate and 20-fold
lower molar concentration than Gadopentetate. In addition, we
computed a parameter referred to as contrast agent uptake ratio
(CUR), by relating the equilibrium X-ray attenuation of the cartilage
after exposure to the contrast agent to the X-ray attenuation of the
contrast agent alone in solution.
We hypothesized that when compared with the starting
concentration of the contrast agent the partitioning of the
contrast agent in the cartilage will be correlated with the charge
on each contrast agent. The electrostatic attraction of the cationic
contrast agent to the anionic GAGs in cartilage will result in
signiﬁcantly higher equilibrium partitioning of the cationic
contrast agent in the cartilage ECM, hence resulting in a greater
than one CUR value compared to a CUR value for Ioxaglate (1)
and Gadopentetate (2) of less than one. Based on the number of
charges, the magnitude of the CUR value will be greatest for the
CA4þ agent and least for Gadopentetate. In addition, the cationic
agent will be able to generate signiﬁcant correlations with the
natural variations of GAG in cartilage even at the lower
concentration used compared to Ioxaglate and Gadopentetate
using mCT.Fig. 1. Chemical structure of the conMethods
Synthesis of the cationic contrast agent
The synthetic procedure for the cationic contrast agent has been
previously published33. Themolecular weight and estimated length
and width for Ioxaglate is 1,268.87 g/mol with a length of 26 Å and
width of 13 Å; for CA4þ it is 1,354.03 g/mol with length of 29 Å and
width of 18 Å; and for Gadopentetate it is 562.61 g/mol with
a length of 18 Å and width of 11 Å.
Contrast agent preparation
The Ioxaglate solution was prepared from Hexabrix320 (Mal-
linckrodt, MO, USA) by diluting it 20 times with 0.9% saline solu-
tion, resulting in a solution that contained 16 mg of iodine/mL or
0.02 M, and a CT attenuation of 935 Hounsﬁeld Units (HU). This
concentration has been utilized by investigators and has been
shown to generate statistically signiﬁcant correlations with GAG
content31,37. Similarly, the concentration for gadoliniumwas chosen
based on the most frequent concentration used by reports in the
literature28,36. Therefore, the gadolinium contrast agent solution
was diluted to a 0.2 M solution from Magnevist using 0.9% saline.
This high molar concentration gave an attenuation of 1,354 HU. The
cationic contrast agent solution was prepared such that they had
half of the iodine concentration as the anionic contrast agent
solution (CT attenuation¼ 467 HU; 8 mg of iodine/mL or 0.01 M).
The appropriate amount of CA4þwas dissolved in deionized water
and the pH of each solutionwas then adjusted to pH 7.4 with NaOH.
The osmolality of each contrast agent was adjusted with NaCl to
match the in-situ osmolality of articular cartilage, 400 mOsm45.
Specimen preparation
A diamond tipped cylindrical cutter irrigated with 0.9% saline at
room temperature was used to extract 7 mm diameter osteo-
chondral plugs from the femoral condyles of ﬁve knee joints from
1 to 2 year old freshly slaughtered cows. Altogether, we used ten
plugs for this study. All the samples were frozen at 20C with
protease inhibitors and sodium azide for later use. 5 mM of EDTA
and Benzamidine HCL was used to prepare a cocktail of protease
inhibitors (St. Louis, MO, USA) which was included in all the
solutions that came in contact with the cartilage to prevent
nonspeciﬁc degradation of the cartilage during the study.
CECT imaging
Baseline imaging
All osteochondral samples and contrast agent solutions used in
this study were ﬁrst scanned using the micro computed tomo-
graphic (mCT) imaging system (mCT40, Scanco Medical AG, Brütti-
sellen, Switzerland) to obtain the baseline attenuation values for
the non-enhanced cartilage volume and the contrast agent solu-
tions. Non-enhanced, native cartilage tissue has a CT attenuation
baseline ranging from 25 to 135 HU.trast agents used in this study.
Table I
Calculated CUR values for the contrast agents investigated
Agent Mw g/mol Formal charge CUR
Gadopentetate or Magnevist 562.61 2 0.52 0.17
Ioxaglate or Hexabrix 1,268.87 1 0.62 0.26
CA4þ 1,354.03 þ4 2.38 0.26
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After the baseline imaging, the cartilage samples were sequen-
tially immersed inall three contrast agents (Ioxaglate,Gadopentetate,
and CA4þ). Speciﬁcally, the samples were immersed in each contrast
agent for 24 h, scanned using the mCT imaging system, and subse-
quently washed for 24 h in saline before they were immersed in the
following contrast agent. This time was more than sufﬁcient as the
contrast agent reached a maximumvalue, or equilibrium value, after
about 8 h31,37e39. CT measurements were performed after the 24-h
wash-out step and conﬁrmed that the contrast agent had left the
tissue and that the CT attenuation had returned to baseline prior to
immersion in the next contrast agent (see SI). We chose to keep the
ﬁxedorderof imaging (Ioxaglate,Gadopentetate, andCA4þ) since the
CA4þ had the highest afﬁnity and slowest diffusion out of the carti-
lage. The diffusion out or wash out time for CA4þ in the plugs was
slowwith roughly 50% of theCTattenuation remaining after 24 h (see
SI). Using the CA4þ earlier in the series would have required a longer
overall study and a greater chance of CA4þ remaining in the tissue to
affect the results of the next agent to be studied. The cartilage surface
was blotted to remove excess contrast agent and the plugs were
positioned in the mCT imaging system using a custom airtight holder
which was able to hold all 10 plugs while keeping them in a humid
environment to prevent drying of the cartilage tissue.
Sequential transaxial images of the cartilage and underlying
subchondral bone were acquired using the mCT imaging system at
an isotropic voxel resolution of 36 mm3, 70 kVP tube voltage,
113 uAmp current and 300 ms integration time. The imaging
parameters were kept constant across all groups. The sequential
slices obtained using the mCT system were then converted into the
standard image format (DICOM) using the proprietary software
from Scanco Medical. This data was then analyzed using commer-
cial image processing software (Analyze, BIR, Mayo Clinic,
Rochester, MN, USA). The 3D mCT data sets were imported into
Analyze and the cartilage was segmented from the subchondral
bone using a 3D semi-automatic threshold based segmentation
algorithm. During the segmentation process, multiple steps such as
thresholding, component labeling and registration were utilized to
conﬁrm accurate cartilage segmentation. In all cases, a trained user
conﬁrmed that the segmentation accurately reﬂected the cartilage
tissue based on a clear visualization of the cartilageebone interface.
The mean cartilage X-ray attenuation values for each sample were
obtained by averaging attenuation values for all cartilage tissue
overall transaxial mCT images. The average X-ray attenuation
reported in this study represents the grayscale intensities in HU.
Biochemical assessment of GAG content
After the last scan and saline wash-out step, the samples were
prepared for biochemical analysis using the 1,9-dimethylmethylene
blue (DMMB) colorimetric assay as described in the SI46.
CUR
The CUR for the three contrast agents was computed using
Equation (1). Based on the charge of the GAGs, the anionic contrast
agents will be excluded from the GAG-rich areas and the cationic
contrast agent will be attracted towards areas with high GAG.
Hence, when comparing two anionic contrast agents, the anionic
contrast agent that is excluded more for the same amount of unit
GAGs is superior because it provides a higher change in X-ray
attenuation for the same amount of change in per unit GAGs of
a given tissue volume. Similarly, for cationic contrast agents,
a higher uptake of the cationic contrast agent for the same amount
of GAG is better because it provides more attenuation per unit of
GAG molecules in a given volume of tissue.Contrast Agent Uptake RatioðCURÞ
¼ CECT Cartilage=CECT Contrast Agent (1)
where,
CECT_Cartilage¼ the attenuation of cartilage in HU after equil-
ibration in a particular contrast agent.
CECT_Contrast¼ the attenuation of the contrast agent solution
in HU.
For anionic contrast agents, CUR <1, indicating exclusion.
For cationic contrast agents, CUR >1, indicating afﬁnity.
Statistical analysis
Normality of the samples was determined and conﬁrmed using
the ShapiroeWilk test. Partial correlation analysis was used to
express the CT attenuation of the contrast agents partitioned
throughout the cartilagemeasured by mCTas a linear function of the
GAG content measured by the DMMB assay, to account for multiple
dependent samples across the groups. The coefﬁcient of determi-
nation (R2) was used as the criterion to compare the different
regression models. Our strategy was based on the Fisher r-to-z
transformation with a back-transformation of the bounds to
produce a 95% conﬁdence interval (CI) for the difference between
the correlations being compared (GAG content per wet weight of
cartilage (%) vs CT attenuation (HU) for CA4þ, Ioxaglate and
Gadopentetate). This strategy includes the 95% CI and Z test with
a two-sided P value to test for differences between the correlations.
For the CUR values, one-way ANOVA in conjunction with
a TukeyeKramer HSD test was conducted to compare the mean
CUR values for the three contrast agent groups. All statistical
analyses were conducted using SPSS 17.0 (SPSS, Chicago, IL, USA).
Results
CURs
The CUR values for the contrast agents (Ioxaglate, Gadopente-
tate, and CA4þ) were computed using Equation (1). The CUR was
2.38 0.26, 0.62 0.26 and 0.52 0.17 (mean SD) for the CA4þ,
Ioxaglate and Gadopentetate contrast agents respectively (Table I).
The increase in uptake for the CA4þ was 2.38 fold more when
compared with the concentration of the initial solution, indicating
signiﬁcant enhancement of the cartilage tissue. As expected, the
uptake of the anionic agents was lower than the concentration of
their initial solutions. Ioxaglate and Gadopentetate were 38% and
48% excluded compared to their initial concentrations, respectively,
and had CUR values less than one. The CUR for CA4þ was signiﬁ-
cantly higher than Ioxaglate and Gadopentetate (P< 0.0001),
however the difference between the CUR for Gadopentetate and
Ioxaglate was non-signiﬁcant (P¼ 0.098).
Comparison of the ability of the contrast agents to monitor changes
in GAG content
The cationic contrast agent equilibrated in the ECM in direct
proportion to the GAG content, exhibiting the opposite trend
compared to the anionic contrast agents (Fig. 2). Ioxaglate
Fig. 2. Linear regression analysis of average CT attenuation vs GAG content for three
different contrast agents (Ioxaglate¼ red circles, Gadopentetate¼ green triangles,
CA4þ¼ blue diamonds). CT attenuation values are displayed in HU. GAG content
reported as (mg of GAG)/(mg of hydrated cartilage).
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exhibited a non-signiﬁcant correlation with GAG content. The
positively charged CA4þ displayed a statistically signiﬁcant corre-
lation with GAG content (R2¼ 0.83, P< 0.001). The coefﬁcient of
determination value for the CA4þ indicated that the CECT attenu-
ation obtained using the CA4þ was able to account for 83% of the
changes in the GAG content. Moreover, the steep positive slope of
the regression line indicates that small changes in GAG concen-
trations can be monitored using CA4þ.
Figure 3 shows representative 3D color map images of the same
osteochondral plug for each contrast agent. The images clearly
show that the cationic contrast agent is able to reﬂect the natural
distribution of GAGs, with few GAGs in the superﬁcial tangential
zone (i.e., lower attenuation values) and higher GAG content in the
middle and deep zones of the tissue (higher attenuation values). By
comparison, the analogous trends are not observed with the
anionic contrast agents, Ioxaglate (1) and Gadopentetate (2)
even when the scale is compressed.Fig. 3. Three dimensional CECT images of the same sample exposed to the three contrast age
the cationic contrast agent (CA4þ) reﬂects the depth-wise inhomogeneous distribution of G
the concentration used.Discussion
The primary aims of this mCT study were to (1) quantify the
uptake of a 2, 1 and þ4 charged contrast agent in cartilage; (2)
correlate naturally occurring variations in GAG content to CT
attenuation using CECT; (3) visualize the GAG distribution in ex vivo
cartilage plugs; and (4) determine if a reduced concentration of
CA4þ, compared to Ioxaglate and Gadopentetate, could be used for
quantitative CECT imaging of cartilage. To quantify the uptake of
the contrast agent in the cartilage ECM, we determined the CUR for
all three contrast agents, which is a ratio of the equilibrium X-ray
attenuation in the cartilage ECM with the concentration of the
contrast agent alone in solution (Table I). When the CUR value is
one, the concentration of the contrast agent in the solution and
cartilage tissue sample are the same. The CUR value for the cationic
contrast agent (CA4þ) was greater than one and equal to 2.38
indicating an increase in the attenuation of 238% when compared
to the original solution. This increase can be attributed to the
cationic nature of the contrast agent (CA4þ) and high negative
ﬁxed charge density of cartilage. For the anionic agents, the CUR
value was <1. Speciﬁcally, the CUR value for Ioxaglate was 0.62 and
for Gadopentetate was 0.52. The values of <1 indicate exclusion of
the anionic contrast agents from the cartilage ECM due to the high
negative ﬁxed charge density of cartilage. The magnitude of the
CUR value represents the degree of exclusion for the anionic
contrast agents with a smaller CUR value indicating a lesser amount
of contrast agent in the cartilage. Thus, the reduced uptake of
Gadopentetate and Ioxaglate compared to CA4þ can be explained
by the difference in the overall charge.
The correlation plot between the CECT attenuation and GAG
content in ex vivo bovine plugs (Fig. 2) indicates that the CA4þ
contrast agent was sensitive to changes in GAG concentration and
could account for 83% of the variation in GAG content (R2¼ 0.83,
P¼ 0.0003). The correlation between CECT attenuation and GAG
content for Ioxaglate and Gadopentetate (R2¼ 0.22, P¼ 0.17 and
R2¼ 0.2, P¼ 0.19, respectively) was not signiﬁcant. In our previous
work, we have shown a positive result in bovine osteochondral
plugs degraded using chondroitinase ABC and pQCT with the CA4þ
and Iothalamate or Cysto Conray II (Mallinckrodt, MO, USA)39. The
lack of correlation with Ioxaglate is likely attributed to the lownts used in the study. Color bar indicates the CECT attenuation in HU. The distribution of
AGs in articular cartilage. Ioxaglate or Gadopentetate fail to reﬂect this distribution at
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the non-signiﬁcant correlation with Gadopentetate is counter to
what has been shown in the study by Cockman and colleagues36.
There are several key differences that may have led to this result.
First, the type of the tissue used by Cockman and colleagues was
bovine nasal cartilage and we utilized bovine knee articular carti-
lage. Bovine nasal cartilage is more homogenous and ﬁbrocartilage
like, which may alter the partitioning of the contrast agents in the
ECM. Second, enzymatically degraded samples, as used by Cock-
man, will generally provide wider changes in GAG content which is
more conducive for better correlations than the narrow, range of
GAG content in healthy cartilage tissue.
The 3D CECT images (Fig. 3) show that CA4D is capable of
reﬂecting the inhomogeneous distribution of GAGs that occurs
naturally in articular cartilage. The superﬁcial zone consists mostly
of highly oriented collagen ﬁbrils, while the middle and deep zones
contain more GAGs. Accordingly, the images obtained with CA4D
clearly show higher attenuation values in the middle and deep
zones of the articular cartilage. This trend also rules out the
possibility that the contrast agent distribution is dominated by
incomplete diffusion into the tissue which has been an issue sus-
pected of confounding the interpretation of similar studies with
anionic contrast agents. By comparison, it is difﬁcult to observe
similar local variations in GAG content when Ioxaglate and Gado-
pentetate were used.
In this study we chose to compare our new CA4þ contrast agent
with Ioxaglate (1) and Gadopentetate (2), which are two widely
used FDA approved contrast agents. As such, we need to be mindful
of the comparisons as we are relating contrast agents bearing
formal charges of 2 to 1 to þ4. Ideally it would be best to
compare, for example, a 2 to a þ2 of nearly the same chemical
structure, but this is not readily accomplished as those compounds
are not commercially available, previously reported in the litera-
ture, or easily synthesized. However, the CUR and GAG correlation
data do indicate that contrast agent charge can have a pronounced
effect on CECT imaging of cartilage. A CUR value of one exists when
the concentration of contrast agent is the same in the bathing
solution and cartilage tissue and, thus, a CUR value that deviates
from one with the largest magnitude will likely be associated with
the best contrast agents for predicting GAG content. In this study
we showed that a greater CUR value and deviation from one was
obtained with the CA4þ at a lower mgI/mL concentration thanwith
Ioxaglate. With the data herein, we are unable to deﬁne the
mechanism of electrostatic interaction responsible for the CUR. In
one scenario, a Donnan equilibrium is present where the negative
ﬁxed charge of cartilage enhances or diminishes uptake (or parti-
tioning) of a positive or negative contrast agent, respectively. For
a cationic contrast agent, there is another possibility of electrostatic
binding between the agent and the GAG when the attractive
interaction is sufﬁciently strong. Both mechanisms will give
a predictable relationship between CT attenuation and GAGs when
using a contrast agent. Consequently, studies are planned to
elucidate the mechanism (binding or Donnan partitioning) of
electrostatic interaction between the GAGs and contrast agent.
Previous studies with singly charged ions (Naþ) and cartilage
explants have shown that the interaction with GAG can be
described by Donnan partitioning47,48, whereas the binding of
multi-charged molecules (peptides) to GAG can be electrostatic
binding or Donnan partitioning depending on the speciﬁc compo-
sition under investigation49,50.
It has been suggested that having multiple charges of either
polarity would afford sensitive imaging of GAGs in cartilage13;
however, our results show that with two negative charges, wewere
unable to generate better correlations with GAG content thanwhen
using an agent with one negative charge. The poor coefﬁcient ofdetermination values for Ioxaglate and Gadopentetate in this study
highlights the drawbacks of using electrostatic repulsion as
a means to enhance imaging of GAGs in cartilage. Thus, to obtain
better correlations, higher concentrations of the anionic contrast
agents are needed with z80 mgI/mL or more affording strong
correlations. Taken together, our results show that imaging with
the cationic contrast agent can be performed at lower concentra-
tions than an anionic agent (e.g., 8 mgI/mL CA4þ vs 16 mgI/mL
Ioxaglate).
The cationic contrast agent utilized in this study may be a useful
agent for in vivo imaging of GAGs in articular cartilage. The elec-
trostatic attraction of the cationic contrast agent will bode well for
its usage in the in vivo scenario whereby a lower concentration of
the contrast agent will lead to less material being injected to obtain
similar (or better) enhancement of the cartilage. From an image
data acquisition standpoint the lower concentration should miti-
gate the beam hardening artifacts associated with the use of high
concentrations of iodinated CT contrast agents in CT arthrography
techniques as well as aid in segmentation of the cartilage from the
bone and synovial ﬂuid51. Additionally, injecting a lower concen-
tration of contrast agent should potentially reduce the toxicological
proﬁle of the agent. These issues will need to be addressed and
experiments are planned for the future. However, before clinical
application of these contrast agents several further steps need to be
taken. The ﬁrst and foremost step would be to show that these
agents can be safely injected in vivo in small and large animals, and
are able to replicate their performance seen in ex vivo tissue
models. The potential risks associated with radiation that is
inherent to any CT based method should also be taken into account.
Conclusions
In summary, we have evaluated three contrast agents (Gado-
pentetate [2], Ioxaglate [1], and CA4þ [þ4]) which possess
varying charges from 2 to þ4 in an ex vivo bovine osteochondral
plug model using mCT. The CUR was calculated. For the anionic
contrast agents, the CUR was 0.62 for Ioxaglate and 0.52 for
Gadopentetate, indicating exclusion of 38% Ioxaglate and 48%
Gadopentetate from the cartilage extracellular matrix. The CURwas
2.38 for the cationic contrast agent, CA4þ, indicating a 2.38 fold
increase in CT attenuation of the cartilage compared to the solution.
The magnitude of CUR was greatest for CA4þ and this afﬁnity for
GAGs led to signiﬁcantly higher attenuations at lower iodine
concentrations. We then evaluated the ability of the three contrast
agents to image and to correlate the CT attenuation to the naturally
occurring variations in GAG content of bovine articular cartilage
using mCT. The cationic contrast agent exhibited a signiﬁcant
correlation between CT attenuation and GAG content compared to
Ioxaglate and Gadopentetate, respectively (R2¼ 0.83, compared
with R2¼ 0.20 for Ioxaglate and R2¼ 0.22 for Gadopentetate).
Further development of CECT based imaging methods for quanti-
tative assessment of the biochemical and biomechanical state of
cartilage will lead to a fast, easily available, high resolution imaging
technique that can facilitate preclinical and clinical development of
new disease-modifying therapies, as well as follow the progression
of cartilage diseases and treatment outcomes in patients.
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